HRP20100563T1 - Derivati dihidropirazolopirimidinona - Google Patents

Derivati dihidropirazolopirimidinona Download PDF

Info

Publication number
HRP20100563T1
HRP20100563T1 HR20100563T HRP20100563T HRP20100563T1 HR P20100563 T1 HRP20100563 T1 HR P20100563T1 HR 20100563 T HR20100563 T HR 20100563T HR P20100563 T HRP20100563 T HR P20100563T HR P20100563 T1 HRP20100563 T1 HR P20100563T1
Authority
HR
Croatia
Prior art keywords
group
phenyl
dihydro
amino
salt
Prior art date
Application number
HR20100563T
Other languages
English (en)
Croatian (hr)
Inventor
Sakamoto Toshihiro
Sunami Satoshi
Yamamoto Fuyuki
Niiyama Kenji
Bamba Makoto
Takahashi Keiji
Furuyama Hidetomo
Sagara Takeshi
Otsuki Sachie
Nishibata Toshihide
Yoshizumi Takashi
Hirai Hiroshi
Original Assignee
Banyu Pharmaceutical Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100563(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyu Pharmaceutical Co. filed Critical Banyu Pharmaceutical Co.
Publication of HRP20100563T1 publication Critical patent/HRP20100563T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20100563T 2006-04-27 2007-04-25 Derivati dihidropirazolopirimidinona HRP20100563T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27
PCT/JP2007/059408 WO2007126122A1 (fr) 2006-04-27 2007-04-25 Dérivés de dihydropyrazolopyrimidinones

Publications (1)

Publication Number Publication Date
HRP20100563T1 true HRP20100563T1 (hr) 2010-11-30

Family

ID=38655640

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20100563T HRP20100563T1 (hr) 2006-04-27 2007-04-25 Derivati dihidropirazolopirimidinona
HRP20161763TT HRP20161763T1 (hr) 2006-04-27 2007-04-25 Derivati dihidropirazolopirimidinona

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20161763TT HRP20161763T1 (hr) 2006-04-27 2007-04-25 Derivati dihidropirazolopirimidinona

Country Status (38)

Country Link
US (4) US7834019B2 (fr)
EP (2) EP2017278B1 (fr)
JP (2) JP4513919B2 (fr)
KR (1) KR101409161B1 (fr)
CN (1) CN101432284B (fr)
AR (1) AR060635A1 (fr)
AT (1) ATE475662T1 (fr)
AU (1) AU2007244185B2 (fr)
BR (1) BRPI0710081A2 (fr)
CA (1) CA2650119C (fr)
CR (1) CR10359A (fr)
CY (2) CY1111069T1 (fr)
DE (1) DE602007008085D1 (fr)
DK (2) DK2016080T3 (fr)
DO (1) DOP2007000084A (fr)
EC (1) ECSP088812A (fr)
ES (2) ES2348751T3 (fr)
GT (1) GT200800211A (fr)
HN (1) HN2008001532A (fr)
HR (2) HRP20100563T1 (fr)
HU (1) HUE032987T2 (fr)
IL (1) IL194367A (fr)
LT (1) LT2017278T (fr)
MA (1) MA30428B1 (fr)
MX (1) MX2008013063A (fr)
MY (1) MY145408A (fr)
NO (1) NO341617B1 (fr)
NZ (1) NZ571196A (fr)
PE (1) PE20080695A1 (fr)
PL (2) PL2016080T3 (fr)
PT (2) PT2016080E (fr)
RU (1) RU2437885C2 (fr)
SI (2) SI2016080T1 (fr)
SV (1) SV2009003060A (fr)
TW (1) TWI409262B (fr)
UA (1) UA96152C2 (fr)
WO (2) WO2007126128A1 (fr)
ZA (1) ZA200807748B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US8198281B2 (en) * 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
WO2008141385A1 (fr) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Inhibiteurs de polymérases virales
US8329711B2 (en) * 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
ES2430053T3 (es) * 2008-06-12 2013-11-18 Merck Sharp & Dohme Corp. Procedimiento para producir derivados de bicicloanilina
US8575179B2 (en) 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
WO2010076887A1 (fr) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Biomarqueurs prédictifs utiles pour une thérapie anticancéreuse à médiation par un inhibiteur de wee1
US8288396B2 (en) 2009-02-25 2012-10-16 Msdkk Pyrimidopyrimidoindazole derivative
WO2011027800A1 (fr) * 2009-09-02 2011-03-10 Banyu Pharmaceutical Co.,Ltd. Utilisation de biomarqueur(s) pour identifier un patient répondant à l'inhibiteur de wee1 et méthodes de traitement du cancer à médiation par p53 dysfonctionnel ou adhérent par l'administration d'un inhibiteur de wee1
HRP20140821T1 (hr) 2009-09-15 2014-10-10 Merck Sharp & Dohme Corp. Priprema kristalnih hemihidratnih oblika dihidropirazolopirimidinona
TW201304778A (zh) 2010-11-16 2013-02-01 Array Biopharma Inc 檢查點激酶１抑制劑及ｗｅｅ１激酶抑制劑之組合
KR102093947B1 (ko) * 2011-04-27 2020-03-26 제온 코포레이션 중합성 화합물, 중합성 조성물, 고분자, 및 광학 이방체
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP2755482B1 (fr) 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combinaison de mk-1775 et mk-8776 pour le traitement du cancer
CA2851640A1 (fr) 2011-10-20 2013-04-25 Abbvie Inc. Composes de pyridopyrimidinone inhibiteurs de kinases
MX2014010176A (es) * 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
WO2014062454A1 (fr) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions et procédés de traitement du cancer
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
CA2909160C (fr) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations d'oxabicycloheptanes et d'oxabicycloheptenes
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
RU2689557C2 (ru) * 2014-12-17 2019-05-28 Дельта-Флай Фарма, Инк. Применение фармацевтической композиции для лечения или создания условий ремиссии у пожилого пациента с солидным раком
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
WO2016168633A1 (fr) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones utilisées en tant que modulateurs de la signalisation du tnf
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
ES2799520T3 (es) * 2015-09-01 2020-12-18 Taiho Pharmaceutical Co Ltd Compuestos de pirazolo[3,4-d]pirimidina o sales de los mismos
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
CA3003737C (fr) * 2015-11-01 2021-09-14 The Regents Of The University Of Colorado, A Body Corporate Inhibiteurs de la kinase wee1 et leurs procedes de fabrication et d'uti lisation
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
SI3512833T1 (sl) 2016-09-15 2020-11-30 Boehringer Ingelheim International Gmbh Heteroarilne karboksamidne spojine kot inhibitorji RIPK2
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
WO2018107004A1 (fr) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes pour la modulation de la réponse immunitaire
ES2902050T3 (es) * 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2018171633A1 (fr) * 2017-03-23 2018-09-27 上海迪诺医药科技有限公司 Dérivé macrocyclique de pyrazol[3,4-d]pyrimidin-3-one, composition pharmaceutique et utilisation associée
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
MX2020001235A (es) 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
WO2019037678A1 (fr) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 Dérivé de pyrazolo[3,4-d]pyrimidin-3-one, composition pharmaceutique et utilisation associée
WO2019074981A1 (fr) 2017-10-09 2019-04-18 GiraFpharma LLC Composés hétérocycliques et leurs utilisations
WO2019074979A1 (fr) * 2017-10-09 2019-04-18 Girafpharma, Llc Composés hétérocycliques et leurs utilisations
PT3712150T (pt) 2017-11-01 2024-08-22 Wuxi Biocity Biopharmaceutics Co Ltd Composto macrocíclico que serve como inibidor wee1 e aplicações do mesmo
WO2019096322A1 (fr) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 Composé de pyrazolone-pyrimidine, son procédé de préparation et son application
CN111315747B (zh) * 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
WO2019165204A1 (fr) 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. Composés de 1,2-dihydro-3 h-pyrazolo [3,4-d] pyrimidine-3-one utilisés en tant qu'inhibiteurs de la kinase we -1
CA3088997A1 (fr) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Inhibiteurs de la kinase wee1 et methodes de traitement du cancer a l'aide de ces inhibiteurs
US11261192B2 (en) * 2018-03-09 2022-03-01 Recurium Ip Holdings, Llc Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
JP7481336B2 (ja) * 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
JP2022528047A (ja) * 2019-03-22 2022-06-08 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド Ｗｅｅ１阻害剤、その製造および用途
WO2020210375A1 (fr) 2019-04-09 2020-10-15 Nuvation Bio Inc. Composés hétérocycliques et leurs utilisations
US20220220115A1 (en) * 2019-04-09 2022-07-14 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210320A1 (fr) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées
US12291536B2 (en) 2019-04-30 2025-05-06 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of Wee1 inhibitor compound and use thereof
CN112142748B (zh) 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN112142747B (zh) * 2019-06-28 2024-03-01 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
JP2022554157A (ja) 2019-10-25 2022-12-28 アストラゼネカ・アクチエボラーグ がんを処置する方法
MX2022007628A (es) * 2019-12-20 2022-08-25 Recurium Ip Holdings Llc Combinaciones.
CN113387962A (zh) * 2020-03-12 2021-09-14 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US12522607B2 (en) 2020-06-17 2026-01-13 Wigen Biomedicine Technology (shanghai) Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
KR102549484B1 (ko) * 2020-12-08 2023-06-29 한국화학연구원 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
CN116867787A (zh) * 2021-02-09 2023-10-10 微境生物医药科技(上海)有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171128A1 (fr) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 Dérivé de pyrazolo[3,4-d]pyrimidine-3-cétone servant d'inhibiteur de wee-1
WO2022171126A1 (fr) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 Composé cyclique fusionné utilisé comme inhibiteur de wee-1
CN115197221B (zh) * 2021-04-02 2024-05-24 轩竹(北京)医药科技有限公司 二氢吡唑并嘧啶酮类大环衍生物及其用途
IL307863A (en) 2021-04-29 2023-12-01 Novartis Ag Diubiquitinase-directed chimeras and related methods
EP4332104A4 (fr) 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Composé à cycle fusionné utilisé comme inhibiteur de wee-1, son procédé de préparation et son utilisation
JP2024520969A (ja) 2021-05-28 2024-05-28 江蘇天士力帝益薬業有限公司 Ｗｅｅ１阻害剤とその用途
KR20240044409A (ko) * 2021-06-04 2024-04-04 아프레아 테라퓨틱스, 인크. Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체
TW202328142A (zh) * 2021-09-18 2023-07-16 香港商優領醫藥科技(香港)有限公司 含嘧啶并二氫吡唑啉酮類衍生物、其藥學上可接受的鹽及其製備方法和應用
CN113880844B (zh) * 2021-09-29 2023-02-14 武汉九州钰民医药科技有限公司 Wee1蛋白激酶抑制剂adavosertib的化学合成方法
CN113735863A (zh) * 2021-09-29 2021-12-03 武汉九州钰民医药科技有限公司 Wee1抑制剂adavosertib的制备工艺
TW202322812A (zh) * 2021-11-01 2023-06-16 大陸商正大天晴藥業集團股份有限公司 吡唑［３，４－ｄ］嘧啶－３－酮類化合物、包含其的藥物組合物及其醫藥用途
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN115073460B (zh) * 2022-07-13 2023-07-25 苏州施安鼎泰生物医药技术有限公司 一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
CN119497714A (zh) * 2022-07-15 2025-02-21 映恩生物制药（苏州）有限公司 一种嘧啶并五元杂环化合物、其制备方法和用途
CN119798282A (zh) * 2023-10-11 2025-04-11 智擎生技制药股份有限公司 基于稠合吡啶环的Myt1抑制剂
WO2025101691A1 (fr) 2023-11-08 2025-05-15 Exelixis, Inc. Méthodes de traitement du cancer à l'aide de composés inhibant pkmyt1

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井製薬工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
JP2848958B2 (ja) 1990-09-28 1999-01-20 スミスクライン・ビーチャム・コーポレイション 水溶性カンプトテシン類似体、方法および手段
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
CA2483496A1 (fr) 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibiteurs de checkpoint kinases (wee1 et chk1)
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
AU2004212421B2 (en) * 2003-02-07 2009-08-20 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
EP2433943B1 (fr) 2004-07-01 2013-09-11 Daiichi Sankyo Company, Limited Intermédiaires pour dérivés de thiénopyrazole ayant une activité inhibitrice de la PDE7
EP1846408B1 (fr) * 2005-01-14 2013-03-20 Janssen Pharmaceutica NV Composé hétérocyclique pyrimidine fusionné à cinq branches comme inhibiteur de kinase
WO2006091737A1 (fr) 2005-02-24 2006-08-31 Kemia, Inc. Modulateurs de l'activite de gsk-3
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Also Published As

Publication number Publication date
CA2650119C (fr) 2017-03-14
IL194367A0 (en) 2009-08-03
HN2008001532A (es) 2009-06-10
GT200800211A (es) 2009-04-07
JP4513919B2 (ja) 2010-07-28
TW200811176A (en) 2008-03-01
NO20084968L (no) 2008-11-26
WO2007126128A1 (fr) 2007-11-08
JPWO2007126128A1 (ja) 2009-09-17
PT2016080E (pt) 2010-10-14
DE602007008085D1 (en) 2010-09-09
US20070254892A1 (en) 2007-11-01
DK2017278T3 (en) 2017-02-13
HRP20161763T1 (hr) 2017-02-24
CR10359A (es) 2009-02-19
AU2007244185A1 (en) 2007-11-08
MX2008013063A (es) 2008-12-16
ES2609087T3 (es) 2017-04-18
ES2348751T3 (es) 2010-12-13
CA2650119A1 (fr) 2007-11-08
BRPI0710081A2 (pt) 2011-08-02
PL2017278T3 (pl) 2017-10-31
ECSP088812A (es) 2008-11-27
LT2017278T (lt) 2017-01-25
UA96152C2 (en) 2011-10-10
SI2017278T1 (sl) 2017-05-31
US20110189130A1 (en) 2011-08-04
PE20080695A1 (es) 2008-06-28
MY145408A (en) 2012-02-15
US7834019B2 (en) 2010-11-16
CY1118526T1 (el) 2017-07-12
US8791125B2 (en) 2014-07-29
PL2016080T3 (pl) 2011-03-31
AR060635A1 (es) 2008-07-02
TWI409262B (zh) 2013-09-21
PT2017278T (pt) 2017-01-03
EP2016080B1 (fr) 2010-07-28
AU2007244185B2 (en) 2012-10-04
KR20090017491A (ko) 2009-02-18
DOP2007000084A (es) 2007-12-31
US20100063024A1 (en) 2010-03-11
JP5167291B2 (ja) 2013-03-21
KR101409161B1 (ko) 2014-06-19
DK2016080T3 (da) 2010-11-22
EP2016080A4 (fr) 2009-05-13
EP2017278A1 (fr) 2009-01-21
EP2017278A4 (fr) 2009-04-22
CN101432284B (zh) 2012-08-15
HUE032987T2 (en) 2017-11-28
MA30428B1 (fr) 2009-05-04
RU2008146759A (ru) 2010-06-10
SI2016080T1 (sl) 2011-03-31
HK1132498A1 (en) 2010-02-26
CN101432284A (zh) 2009-05-13
JP2010132689A (ja) 2010-06-17
ZA200807748B (en) 2009-10-28
SV2009003060A (es) 2009-04-28
EP2017278B1 (fr) 2016-11-02
IL194367A (en) 2014-12-31
EP2016080A1 (fr) 2009-01-21
US7935708B2 (en) 2011-05-03
ATE475662T1 (de) 2010-08-15
RU2437885C2 (ru) 2011-12-27
US20140303178A1 (en) 2014-10-09
WO2007126122A1 (fr) 2007-11-08
CY1111069T1 (el) 2012-05-23
NZ571196A (en) 2011-03-31
NO341617B1 (no) 2017-12-11

Similar Documents

Publication Publication Date Title
RU2008146759A (ru) Производные дигидропиразолопиримидинона
HRP20161536T1 (hr) Derivat bicikloanilina
EP2213673B1 (fr) Dérivé de dihydropyrazolopyrimidinone substitué par pyridone
ES2580779T3 (es) Pirimidinas fusionadas
AU2009279944B2 (en) Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
EP2155752B1 (fr) Polymorphe de dérivé de dihydropyrazolopyrimidinone comme inhibiteur de la kinase weel
IL292229A (en) Pharmacological combination of prmt5 inhibitors
ES2435804T3 (es) Pirimidinas condensadas como inhibidores de Akt
JP2012518598A5 (fr)
JP2010525057A5 (fr)
AU2008288392B2 (en) Fused bicyclic pyrimidines
RU2009111599A (ru) Новые аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
EP2376493A1 (fr) Dérivé de dihydropyrimidopyrimidine
CA2745959A1 (fr) Derives de dihydropyrimidopirymidine
EP4587127A1 (fr) Composés ciblant brm et méthodes d'utilisation associées
RU2007119776A (ru) Новые аминопиридиновые производные, обладающие селективной aurora a ингибирующей активностью
EP2651949B1 (fr) Pyrimido [1,2-b]indazoles substitués et leur utilisation comme modulateurs de la voie pi3k/akt
WO2025184459A1 (fr) Composés ciblant brm et brg1 et procédés d'utilisation associés
TH79028A (th) อนุพันธ์อะมิโน ไพริดีนชนิดใหม่ที่มีฤทธิ์ยับยั้งแบบมีอำนาจเลือกออโรรา a
EP2050748A1 (fr) Nouveau pyrimidines fusionnés
HK1166984B (en) Fused pyrimidines as akt inhibitors